This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reddy, H. K.D.L. Articles by Reddy, E. P. Search for Related Content PubMed PubMed Citation Articles by Reddy, H. K.D.L. Articles by Reddy, E. P.

Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis

Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania

Requests for reprints: E. Premkumar Reddy, Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Pharmacy Building, 3307 North Broad Street, Philadelphia, PA 19140. Phone: 215-707-4307; Fax: 215-707-1454; E-mail: reddy{at}temple.edu.

Previous work has shown that cyclin D1 expression is required for neu- and ras-induced, but not wnt- or c-myc–induced, breast tumorigenesis in mice. Although cyclin D1 binds and activates cyclin-dependent kinase 4 (Cdk4), thereby mediating activation of a program of E2F-dependent gene expression, it has been suggested that the oncogenic activities of cyclin D1 are independent of Cdk4. To determine whether Cdk4 expression is required for breast tumorigenesis in mice, we have generated compound mice ectopically expressing the neu or wnt oncogenes in the mammary glands of wild-type and Cdk4–/– mice. Our results show that Cdk4 expression is required for efficient neu-induced tumorigenesis but is dispensable for wnt-induced breast tumorigenesis. In contrast to results previously observed in the mammary glands of cyclin D1–/– virgin females, our results show defects in mammary gland development in Cdk4–/– virgin females, suggesting differences in compensatory mechanisms in the absence of either subunit of the cyclin D1/Cdk4 complex. These results suggest that drugs targeted to inhibit Cdk4 activities could be developed to specifically treat certain breast tumors as Cdk4 is not essential for viability.

This article has been cited by other articles:

				A. M. Adon, X. Zeng, M. K. Harrison, S. Sannem, H. Kiyokawa, P. Kaldis, and H. I. Saavedra Cdk2 and Cdk4 Regulate the Centrosome Cycle and Are Critical Mediators of Centrosome Amplification in p53-Null Cells Mol. Cell. Biol., February 1, 2010; 30(3): 694 - 710. [Abstract] [Full Text] [PDF]

				H. K.D.L. Reddy, X. Grana, D. N. Dhanasekaran, J. Litvin, and E. P. Reddy Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation Genes & Cancer, January 1, 2010; 1(1): 69 - 80. [Abstract] [Full Text] [PDF]

				D. Zheng, Y.-Y. Cho, A. T.Y. Lau, J. Zhang, W.-Y. Ma, A. M. Bode, and Z. Dong Cyclin-Dependent Kinase 3-Mediated Activating Transcription Factor 1 Phosphorylation Enhances Cell Transformation Cancer Res., September 15, 2008; 68(18): 7650 - 7660. [Abstract] [Full Text] [PDF]

				G. P. Gupta, J. Perk, S. Acharyya, P. de Candia, V. Mittal, K. Todorova-Manova, W. L. Gerald, E. Brogi, R. Benezra, and J. Massague ID genes mediate tumor reinitiation during breast cancer lung metastasis PNAS, December 4, 2007; 104(49): 19506 - 19511. [Abstract] [Full Text] [PDF]

				G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]